In this issue of the journal, The Society for Clinical Trials, whose members are clinical investigators and regulators in academia, government and industry, has published the rationale for their opposition to US Senate bill S. 1956, the socalled “ACCESS” act, which would allow the marketing of therapies that have undergone only Phase I studies (dose finding and toxicity testing) in humans, to patients with “serious and life-threatening” disease who have exhausted other treatment options. While this bill reflects the views and efforts of some cancer advocates and their supporters, it does not represent the beliefs of the cancer advocacy community overall. The essay that follows is inspired by the need for other voices from the patient and advocacy communities to be heard in this debate.
Get full access to this article
View all access options for this article.
References
1.
1. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med1981; 304: 10-15.
2.
2. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol1988; 6: 1368-1176.
3.
3. Williams SF, Mick R, Desser R, Golick J, Beschomer J, Bitran JD. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol1989; 7: 1824-1130.
4.
4. Kennedy MJ, Beveridge, RA, Rowley, SD, Gordon GB, Abeloff MD, Davidson NE. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst1991; 83: 920-926.
5.
5. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol1992; 10: 102-110.
6.
6. Williams SFGilewski T, Mick R, Bitran JD. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol1992; 10: 1743-1147.
7.
7. Peters WP et al. Adjuvant chemotherapy involving high-dose combination cyclophosphamide, cisplatin, and carmustine and autologous bone marrow support for stage II/III breast cancer involving ten or more lymph nodes (CALGB 8782): a preliminary report, Proc of ASCO1990; 9: 22-22 (abstract).
8.
8. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol1995; 13: 2483-2289.
9.
9. Belanger D, Moore M, Tannock I, How American oncologists treat breast cancer: an assessment of the influence of clinical trials. J Clin Oncol1991; 9: 7-16.
10.
10. Mello MM, Brennan TA. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. Health Aff (Millwood)2001; 20: 101-117.
11.
11. Peters WP, Rogers MC. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer. N Engl J Med1994; 330: 7473-477.
12.
12. Health insurance: coverage of autologous bone marrow transplantation for breast cancer (GAO/HEHS-96-83). http://www.gao.gov/archive/1996/he96083.pdf.
13.
13. Stadtmauer EA, O'Neil A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med2000; 342: 1069-1176. (for others, see Farquahar, below).
14.
14. Rahman ZU, Frye DK, Buzdar AU et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol1997; 15: 3171-3377.
15.
15. Weiss RB, Rifkin RM, Stewart FM et al. High-dose chemotherapy for high-risk primary breast cancer: An on-site review of the Bezwoda study. Lancet2000; 355: 999-1003.
17. Farquhar C, Marjoribanks J, Basser R, Hetrick S, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev2005; CD003142.
18.
18. Farquhar C, Marjoribanks J, Basser R, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev2005; CD003139.
19.
19. Abigail Alliance for Better Access to Developmental Drugs. http://abigail-alliance.org/.
20.
20. Transcript of the November 8, 2005 Meeting of the FDA Oncologic Drugs Advisory Committee, pp. 237-261. http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4191T1.pdf.
21.
21. Goldberg P. An ‘insurgency’ targets randomized trials, demands access to investigational drugs. The Cancer Letter2005; 31: 2-2.
22.
22. FDA to patients: Drop dead. Wall Street Journal, September 24, 2002A18. http://www.mercatus.org/regradar/topnews/archives/003730.php.
23.
23. How about a Kianna's Law?Wall Street Journal, March 24, 2005. http://jiminhofe.com/cgi-data/news_doc/files/210.shtml;http://abigail-alliance.org/3_WSJ_Editorials_Kiannas_Law.pdf.
24.
24. Goldberg P.Op Cit1-16.
25.
25. Subpart H-Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses. Code of Federal Regulations [Title 21, Volume 5, Parts 300 to 499] Department of Health and Human Serviceshttp://www.fda.gov/cder/guidance/append4.pdf.
26.
26. Transcript of ODAC Meeting November 8, 2005, http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4191T1.pdf. Transcript of ODAC Meeting March 12, 2003, http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3936T1.htm.
27.
27. Talarico L, Pazdur R. Expanded access program (EAP) to investigational drugs. Proc of ASCO2004. Abstract 6001 (Abstract, lecture, slides), http://www.asco.org/portal/site/ASCO.
28.
28. Fast Track, Priority Review and Accelerated Approval. From FDA/CDER Oncology Tools website, http://www.accessdata.fda.gov/scripts/cder/onctools/Accel.cfm.
